Investor Presentaiton
Company overview
Financial performance
Oncology
Financial review
2022 priorities
Appendix
Innovation: Pipeline overview
Innovation: Clinical trials
Immunology
Ophthalmology
Neuroscience
Respiratory Disease
Leqvio® - siRNA (regulation of LDL-C)
References
Abbreviations
Cardio-Renal
Global Health
Biosimilars
LeqvioⓇ - siRNA (regulation of LDL-C)
NCT03851705 ORION-5 (CKJX839A12302)
Hypercholesterolemia inc. Homozygous Familial Hypercholesterolemia
(HoFH)
Phase 3
NCT03814187 ORION-8 (CKJX839A12305B)
Indication
Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolaemia
(HeFH) and Homozygous Familial Hypercholesterolemia (HoFH)
Phase 3
Indication
Phase
Phase
Patients
3275
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Proportion of subjects achieving prespecified low density lipoprotein
cholesterol (LDL-C) targets at end of study
Safety and tolerability profile of long term use of inclisiran
Inclisiran sodium 300mg on Day 90 and every 180 days for a planned
duration of 3 years
Patients with HeFH or pre-existing atherosclerotic cardiovascular disease
(ASCVD) on background statin +/- ezetimibe therapy and risk equivalents
(patients from ORION 3, 9, 10 & 11 studies)
LDL-C reduction at Day 150
Patients
56
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Changes in PCSK9, other lipids and lipoproteins
Part 1: inclisiran sodium 300mg or placebo on Day 1 and Day 90
Part 2: inclisiran sodium 300mg on Day 180 for patients who were
randomized to the placebo group only, inclisiran sodium 300mg on Day 270
and then every 6 months for a planned duration of 2 years for all patients
Patients with HoFH with background statin +/- ezetimibe therapy
Read-out
Milestone(s)
2023
Publication
TBD
97 Investor Relations | Q2 2022 Results
Read-out
Milestone(s)
Publication
Q1-2022 (actual)
TBD
NOVARTIS | Reimagining MedicineView entire presentation